Efficacy and safety of routine blood pressure lowering in older patients with diabetes: Results from the advance trial

Toshiharu Ninomiya, Sophia Zoungas, Bruce Neal, Mark Woodward, Anushka Patel, Vlado Perkovic, Alan Cass, Mark Cooper, Diederick Grobbee, Pavel Hamet, Stephen Harrap, Lisheng Liu, Giuseppe Mancia, Carl Erik Mogensen, Neil Poulter, Anthony Rodgers, Bryan Williams, Stephen MacMahon, John Chalmers

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: The efficacy and safety of blood pressure lowering in elderly patients have not been sufficiently investigated in patients with diabetes. Using data from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation study, we assessed the efficacy and safety of routine blood pressure lowering to prevent major clinical outcomes in elderly patients with type 2 diabetes. Methods: Eleven thousand one hundred and forty patients aged at least 55 years with type 2 diabetes (mean 66 ± 6 years) were randomly assigned to perindopril-indapamide or placebo. The primary endpoint was a composite of major macrovascular and microvascular disease. The effects of active treatment on outcomes were estimated in subgroups according to age: below 65, 65-74 and at least 75 years. Results: During a mean 4.3-year follow-up, 1799 (16.1%) patients experienced a major event. Active treatment produced similar relative risk reductions for the primary outcome, major macrovascular disease, death and renal events across age groups (all P heterogeneity >0.3). Over 5 years, active treatment was estimated to prevent one primary outcome in every 21, 71 and 118 patients of at least75, 65-74 and below 65 years, respectively. Similar patterns of benefits were observed for secondary outcomes. There were no differences in the tolerability between randomized allocations across age groups (all P heterogeneity >0.6) Conclusion: Routine administration of perindopril-indapamide lowers blood pressure safely and reduces the risk of major clinical outcomes in patients of at least 75 years with type 2 diabetes. The greater absolute benefits in older patients in this age group were not offset by an increased risk of side effects.

Original languageEnglish
Pages (from-to)1141-1149
Number of pages9
JournalJournal of hypertension
Volume28
Issue number6
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

Blood Pressure
Safety
Indapamide
Perindopril
Type 2 Diabetes Mellitus
perindopril drug combination indapamide
Age Groups
Gliclazide
Risk Reduction Behavior
Vascular Diseases
Placebos
Kidney
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and safety of routine blood pressure lowering in older patients with diabetes : Results from the advance trial. / Ninomiya, Toshiharu; Zoungas, Sophia; Neal, Bruce; Woodward, Mark; Patel, Anushka; Perkovic, Vlado; Cass, Alan; Cooper, Mark; Grobbee, Diederick; Hamet, Pavel; Harrap, Stephen; Liu, Lisheng; Mancia, Giuseppe; Mogensen, Carl Erik; Poulter, Neil; Rodgers, Anthony; Williams, Bryan; MacMahon, Stephen; Chalmers, John.

In: Journal of hypertension, Vol. 28, No. 6, 01.01.2010, p. 1141-1149.

Research output: Contribution to journalArticle

Ninomiya, T, Zoungas, S, Neal, B, Woodward, M, Patel, A, Perkovic, V, Cass, A, Cooper, M, Grobbee, D, Hamet, P, Harrap, S, Liu, L, Mancia, G, Mogensen, CE, Poulter, N, Rodgers, A, Williams, B, MacMahon, S & Chalmers, J 2010, 'Efficacy and safety of routine blood pressure lowering in older patients with diabetes: Results from the advance trial', Journal of hypertension, vol. 28, no. 6, pp. 1141-1149. https://doi.org/10.1097/HJH.0b013e328338a89c
Ninomiya, Toshiharu ; Zoungas, Sophia ; Neal, Bruce ; Woodward, Mark ; Patel, Anushka ; Perkovic, Vlado ; Cass, Alan ; Cooper, Mark ; Grobbee, Diederick ; Hamet, Pavel ; Harrap, Stephen ; Liu, Lisheng ; Mancia, Giuseppe ; Mogensen, Carl Erik ; Poulter, Neil ; Rodgers, Anthony ; Williams, Bryan ; MacMahon, Stephen ; Chalmers, John. / Efficacy and safety of routine blood pressure lowering in older patients with diabetes : Results from the advance trial. In: Journal of hypertension. 2010 ; Vol. 28, No. 6. pp. 1141-1149.
@article{7579d67faa6648af859b3e7cb259da14,
title = "Efficacy and safety of routine blood pressure lowering in older patients with diabetes: Results from the advance trial",
abstract = "Objective: The efficacy and safety of blood pressure lowering in elderly patients have not been sufficiently investigated in patients with diabetes. Using data from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation study, we assessed the efficacy and safety of routine blood pressure lowering to prevent major clinical outcomes in elderly patients with type 2 diabetes. Methods: Eleven thousand one hundred and forty patients aged at least 55 years with type 2 diabetes (mean 66 ± 6 years) were randomly assigned to perindopril-indapamide or placebo. The primary endpoint was a composite of major macrovascular and microvascular disease. The effects of active treatment on outcomes were estimated in subgroups according to age: below 65, 65-74 and at least 75 years. Results: During a mean 4.3-year follow-up, 1799 (16.1{\%}) patients experienced a major event. Active treatment produced similar relative risk reductions for the primary outcome, major macrovascular disease, death and renal events across age groups (all P heterogeneity >0.3). Over 5 years, active treatment was estimated to prevent one primary outcome in every 21, 71 and 118 patients of at least75, 65-74 and below 65 years, respectively. Similar patterns of benefits were observed for secondary outcomes. There were no differences in the tolerability between randomized allocations across age groups (all P heterogeneity >0.6) Conclusion: Routine administration of perindopril-indapamide lowers blood pressure safely and reduces the risk of major clinical outcomes in patients of at least 75 years with type 2 diabetes. The greater absolute benefits in older patients in this age group were not offset by an increased risk of side effects.",
author = "Toshiharu Ninomiya and Sophia Zoungas and Bruce Neal and Mark Woodward and Anushka Patel and Vlado Perkovic and Alan Cass and Mark Cooper and Diederick Grobbee and Pavel Hamet and Stephen Harrap and Lisheng Liu and Giuseppe Mancia and Mogensen, {Carl Erik} and Neil Poulter and Anthony Rodgers and Bryan Williams and Stephen MacMahon and John Chalmers",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/HJH.0b013e328338a89c",
language = "English",
volume = "28",
pages = "1141--1149",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of routine blood pressure lowering in older patients with diabetes

T2 - Results from the advance trial

AU - Ninomiya, Toshiharu

AU - Zoungas, Sophia

AU - Neal, Bruce

AU - Woodward, Mark

AU - Patel, Anushka

AU - Perkovic, Vlado

AU - Cass, Alan

AU - Cooper, Mark

AU - Grobbee, Diederick

AU - Hamet, Pavel

AU - Harrap, Stephen

AU - Liu, Lisheng

AU - Mancia, Giuseppe

AU - Mogensen, Carl Erik

AU - Poulter, Neil

AU - Rodgers, Anthony

AU - Williams, Bryan

AU - MacMahon, Stephen

AU - Chalmers, John

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: The efficacy and safety of blood pressure lowering in elderly patients have not been sufficiently investigated in patients with diabetes. Using data from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation study, we assessed the efficacy and safety of routine blood pressure lowering to prevent major clinical outcomes in elderly patients with type 2 diabetes. Methods: Eleven thousand one hundred and forty patients aged at least 55 years with type 2 diabetes (mean 66 ± 6 years) were randomly assigned to perindopril-indapamide or placebo. The primary endpoint was a composite of major macrovascular and microvascular disease. The effects of active treatment on outcomes were estimated in subgroups according to age: below 65, 65-74 and at least 75 years. Results: During a mean 4.3-year follow-up, 1799 (16.1%) patients experienced a major event. Active treatment produced similar relative risk reductions for the primary outcome, major macrovascular disease, death and renal events across age groups (all P heterogeneity >0.3). Over 5 years, active treatment was estimated to prevent one primary outcome in every 21, 71 and 118 patients of at least75, 65-74 and below 65 years, respectively. Similar patterns of benefits were observed for secondary outcomes. There were no differences in the tolerability between randomized allocations across age groups (all P heterogeneity >0.6) Conclusion: Routine administration of perindopril-indapamide lowers blood pressure safely and reduces the risk of major clinical outcomes in patients of at least 75 years with type 2 diabetes. The greater absolute benefits in older patients in this age group were not offset by an increased risk of side effects.

AB - Objective: The efficacy and safety of blood pressure lowering in elderly patients have not been sufficiently investigated in patients with diabetes. Using data from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation study, we assessed the efficacy and safety of routine blood pressure lowering to prevent major clinical outcomes in elderly patients with type 2 diabetes. Methods: Eleven thousand one hundred and forty patients aged at least 55 years with type 2 diabetes (mean 66 ± 6 years) were randomly assigned to perindopril-indapamide or placebo. The primary endpoint was a composite of major macrovascular and microvascular disease. The effects of active treatment on outcomes were estimated in subgroups according to age: below 65, 65-74 and at least 75 years. Results: During a mean 4.3-year follow-up, 1799 (16.1%) patients experienced a major event. Active treatment produced similar relative risk reductions for the primary outcome, major macrovascular disease, death and renal events across age groups (all P heterogeneity >0.3). Over 5 years, active treatment was estimated to prevent one primary outcome in every 21, 71 and 118 patients of at least75, 65-74 and below 65 years, respectively. Similar patterns of benefits were observed for secondary outcomes. There were no differences in the tolerability between randomized allocations across age groups (all P heterogeneity >0.6) Conclusion: Routine administration of perindopril-indapamide lowers blood pressure safely and reduces the risk of major clinical outcomes in patients of at least 75 years with type 2 diabetes. The greater absolute benefits in older patients in this age group were not offset by an increased risk of side effects.

UR - http://www.scopus.com/inward/record.url?scp=77952468076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952468076&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328338a89c

DO - 10.1097/HJH.0b013e328338a89c

M3 - Article

C2 - 20486273

AN - SCOPUS:77952468076

VL - 28

SP - 1141

EP - 1149

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 6

ER -